1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CANbridge Pharmaceuticals Inc.
  6. Summary
    1228   KYG1821D1097

CANBRIDGE PHARMACEUTICALS INC.

(1228)
  Report
Delayed Hong Kong Stock Exchange  -  02:04 2022-08-09 am EDT
3.350 HKD   +0.60%
07/21Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China
CI
07/15CANbridge Pharmaceuticals Inc. - First Patient Dosed in CAN108 EMBARK Phase 2 Study in Biliary Atresia in China, China Study is Part of Global EMBARK Study
AQ
07/15CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
3.4(c) 3.33(c) 3.33(c) 3.33(c) 3.35 Last
0 3 000 0 5 000 1 000 Volume
+2.10% -2.06% 0.00% 0.00% +0.60% Change
More quotes
Estimated financial data (e)
Sales 2022 90,2 M 13,4 M 13,4 M
Net income 2022 -707 M -105 M -105 M
Net cash position 2022 926 M 137 M 137 M
P/E ratio 2022 -1,71x
Yield 2022 -
Sales 2023 168 M 25,0 M 25,0 M
Net income 2023 -594 M -88,0 M -88,0 M
Net cash position 2023 854 M 126 M 126 M
P/E ratio 2023 -1,70x
Yield 2023 -
Capitalization 1 215 M 180 M 180 M
EV / Sales 2022 3,20x
EV / Sales 2023 2,14x
Nbr of Employees 183
Free-Float 59,7%
More Financials
Company
Cambridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of CANbridge Pharmaceuticals Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CANBRIDGE PHARMACEUTICALS INC.
07/21Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceutica..
CI
07/15CANbridge Pharmaceuticals Inc. - First Patient Dosed in CAN108 EMBARK Phase 2 Study in ..
AQ
07/15CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EM..
CI
07/11CANbridge Pharmaceuticals Signs Gene Therapy Research Agreement
MT
07/07CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Comp..
AQ
07/07CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board
CI
07/05Canbridge Pharmaceuticals Inc. Announces Board Changes
CI
06/11CANbridge Pharmaceuticals Inc. Announces Results from its CAN106 Phase 1 Trial
CI
06/09406,309,920 Ordinary Shares of CANbridge Pharmaceuticals Inc. are subject to a Lock-Up ..
CI
05/17CANbridge Pharma Presents Initial Data from Gene Therapy Research at US Medical Confere..
MT
05/12CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical..
CI
04/03CANbridge Pharmaceuticals Inc. Announces Executive Changes
CI
03/28CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Pha..
CI
03/24CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended..
AQ
03/23CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended Decembe..
CI
More news
News in other languages on CANBRIDGE PHARMACEUTICALS INC.
07/21Canbridge Pharmaceuticals Inc. annonce que le premier patient a reçu une dose dans le c..
07/15CANbridge Pharmaceuticals Inc. annonce l'administration d'une dose au premier patient d..
07/11CANbridge Pharmaceuticals signe un accord de recherche en thérapie génique
07/07CANbridge Pharmaceuticals Inc. forme un conseil consultatif scientifique
07/05Canbridge Pharmaceuticals Inc. annonce des changements au conseil d'administration
More news
Chart CANBRIDGE PHARMACEUTICALS INC.
Duration : Period :
CANbridge Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANBRIDGE PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,33 HKD
Average target price 12,37 HKD
Spread / Average Target 271%
EPS Revisions
Managers and Directors
James Xue Chairman & Chief Executive Officer
Glenn Hassan Chief Financial Officer
Gerald Cox Chief Medical & Development Strategist Officer
Minnie Ke VP-Clinical Development & Medical Affairs
Pauline Li Senior VP-Operations & Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
CANBRIDGE PHARMACEUTICALS INC.-62.50%180
MERCK KGAA-18.02%82 690
KYOWA KIRIN CO. LTD.-0.32%12 575
SK BIOPHARMACEUTICALS CO., LTD.-17.28%4 845
BETTA PHARMACEUTICALS CO., LTD.-32.72%3 305
YUHAN CORPORATION-5.31%3 082